Biomerica

Biomerica PEG

The PEG Ratio (Price/Earnings-to-Growth) of Biomerica (BMRA) as of Oct 26, 2026 is -0.05.

PEG

-0.05

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Biomerica is 2026 -0.05 . PEG Ratio (Price/Earnings-to-Growth) of Biomerica was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biomerica Stock analysis

What does Biomerica do? Biomerica, Inc. generates revenue through the development, manufacture, and marketing of medical diagnostic products for early detection and monitoring of chronic diseases. The company sells diagnostic test kits to clinical laboratories and point-of-care markets, analyzing blood, urine, or fecal specimens to measure specific bacteria, hormones, antibodies, antigens, or other substances. Its flagship product, InFoods IBS, offers diagnostic-guided therapy to identify patient-specific foods that may alleviate Irritable Bowel Syndrome symptoms when removed from the diet. The diagnostic test kits are used by clinical laboratories and point-of-care facilities to detect diseases through specimen analysis. InFoods IBS targets physicians seeking personalized dietary solutions for IBS patients, allowing them to identify foods that improve symptoms when eliminated. Biomerica focuses on chronic disease management with products designed for early detection and monitoring in both laboratory and point-of-care settings. Biomerica's revenue streams include sales of diagnostic test kits to clinical laboratories and point-of-care markets, as well as the InFoods IBS diagnostic-guided therapy product. The company serves healthcare providers and physicians who utilize these tools for patient diagnosis and treatment planning, particularly in managing chronic conditions like IBS through dietary adjustments. Biomerica is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biomerica stock

PEG Ratio (Price/Earnings-to-Growth) of Biomerica is -0.05 in 2026.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Biomerica since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Biomerica with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Biomerica

All Key Metrics — Biomerica